New drug combo vs standard for advanced NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with extranodal NK/T-cell lymphoma (a type of lymphoma) and have not had any treatment for it yet.
- Your cancer must be at stage III or IV, meaning it has spread beyond the original site.
- You need to be between 14 and 70 years old.
- You should have good overall health, with enough blood cells and organ function (like liver and kidneys).
- You cannot have active autoimmune diseases that needed treatment in the last 2 years or have had certain immune-based treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This trial tests whether a new combination of chemotherapy drugs (P-GEMD) works better than the standard combination (P-Gemox) for people with certain types of natural killer/T-cell lymphoma (a rare blood cancer). It's designed for newly diagnosed or advanced-stage patients who haven't been treated yet.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
Hear when a new Extranodal Natural Killer T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.